UPDATE 1-Gilead hepatitis C drug Sovaldi racks up $3.5 bln in quarter
July 23, 2014 at 16:52 PM EDT
July 23 (Reuters) - Gilead Sciences Inc said on Wednesday that its new hepatitis C drug Sovaldi had sales of $3.5 billion in the second quarter, exceeding Wall Street estimates and demonstrating that the furor over its price has not curtailed early use.